Background: Acute myeloid leukemia (AML) is a common hematopoietic tumor with extremely high morbidity and mortality. This study was designed to explore candidate genes that were related to the poor prognosis of AML patients and analyze their relationship with drug sensitivity. Methods: Microarray databases were performed to screen the differentially expressed genes (DEGs). DAVID 6.8 was used for further functional enrichment analysis. The protein-protein interaction (PPI) network was constructed through STRING website and Cytoscape tool. Then, we analyzed and explored the mRNA transcription level, prognosis correlation, and drug sensitivity of the candidate genes in AML via multiple acknowledged databases including the GEPIA, BloodSpot, EMBL-EBI, UALCAN, LinkedOmics, and GSCALite databases. Results: A total of 181 up-regulated DEGs were screened. Three candidate genes (MAP2K3, LST1, and CYTH4) related to poor outcomes of AML patients were identified. Meanwhile, the high expression levels of the three genes were verified in AML patients and AML cell lines, the expression differences of three genes at AML different subtypes were demonstrated. Drug sensitivity analysis displayed the expression levels of MAP2K3, LST1, and CYTH4 were negatively related to drug resistance, indicating that the three genes were sensitive to certain small-molecule drugs (including targeted drugs and non-targeted drugs). Conclusion: In summary, MAP2K3, LST1, and CYTH4 may be potential prognostic indicators for AML, and may be associated with the sensitivity of certain small molecule drugs.
| Published in | Cancer Research Journal (Volume 9, Issue 4) |
| DOI | 10.11648/j.crj.20210904.11 |
| Page(s) | 176-190 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2021. Published by Science Publishing Group |
Acute Myeloid Leukemia (AML), Candidate Gene, Bioinformatics, Prognosis, Drug Sensitivity
| [1] | Rowe JM, Tallman MS. How I treat acute myeloid leukemia [J]. Blood. 2010; 116 (17): 3147-56. |
| [2] | Weinberg OK, Sohani AR, Bhargava P, et al. Diagnostic work-up of acute myeloid leukemia [J]. Am J Hematol. 2017; 92 (3): 317-21. |
| [3] | Cai SF, Levine RL. Genetic and epigenetic determinants of AML pathogenesis [J]. Seminars in hematology. 2019; 56 (2): 84-9. |
| [4] | Li S, Mason CE, Melnick A. Genetic and epigenetic heterogeneity in acute myeloid leukemia [J]. Current opinion in genetics & development. 2016; 36: 100-6. |
| [5] | Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia [J]. J Clin Oncol. 2011; 29 (5): 487-94. |
| [6] | Stein EM, Tallman MS. Emerging therapeutic drugs for AML [J]. Blood. 2016; 127 (1): 71-8. |
| [7] | Dillon R, Hills R, Freeman S, et al. Molecular MRD status and outcome after transplantation in NPM1-mutated AML [J]. Blood. 2020; 135 (9): 680-8. |
| [8] | Roboz GJ. Current treatment of acute myeloid leukemia [J]. Current opinion in oncology. 2012; 24 (6): 711-9. |
| [9] | Yin F, Shu L, Liu X, et al. Microarray-based identification of genes associated with cancer progression and prognosis in hepatocellular carcinoma [J]. J Exp Clin Cancer Res. 2016; 35 (1): 127. |
| [10] | Cai D, Yang Y, Jiang Z, et al. Identification of 11 Differentially Expressed Hub Genes and Their Upstream microRNAs in Nasal-type NK/T-cell Lymphoma Based on Clinical Sample Analysis %J Cancer Research Journal [J]. 2020; 8 (4). |
| [11] | Rung J, Brazma A. Reuse of public genome-wide gene expression data [J]. Nat Rev Genet. 2013; 14 (2): 89-99. |
| [12] | Xu Y, Li X, Han Y, et al. A New Prognostic Risk Model Based on PPAR Pathway-Related Genes in Kidney Renal Clear Cell Carcinoma [J]. PPAR Res. 2020; 2020: 6937475. |
| [13] | Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses [J]. Nucleic Acids Res. 2017; 45 (W1): W98-W102. |
| [14] | Liu CJ, Hu FF, Xia MX, et al. GSCALite: a web server for gene set cancer analysis [J]. Bioinformatics. 2018; 34 (21): 3771-2. |
| [15] | McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation [J]. Nucleic Acids Res. 2012; 40 (10): 4288-97. |
| [16] | Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration [J]. Nucleic Acids Res. 2013; 41 (Database issue): D808-15. |
| [17] | Chin CH, Chen SH, Wu HH, et al. cytoHubba: identifying hub objects and sub-networks from complex i nteractome [J]. BMC Syst Biol. 2014; 8 Suppl 4: S11. |
| [18] | Huang DW, Sherman BT, Tan Q, et al. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists [J]. Genome Biol. 2007; 8 (9): R183. |
| [19] | Bagger FO, Kinalis S, Rapin N. BloodSpot: a database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles [J]. Nucleic Acids Res. 2019; 47 (D1): D881-d5. |
| [20] | Li W, Cowley A, Uludag M, et al. The EMBL-EBI bioinformatics web and programmatic tools framework [J]. Nucleic Acids Res. 2015; 43 (W1): W580-4. |
| [21] | Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses [J]. Neoplasia. 2017; 19 (8): 649-58. |
| [22] | Vasaikar SV, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types [J]. Nucleic Acids Res. 2018; 46 (D1): D956-D63. |
| [23] | Carbon S, Ireland A, Mungall CJ, et al. AmiGO: online access to ontology and annotation data [J]. Bioinformatics. 2009; 25 (2): 288-9. |
| [24] | Lowenberg B, Downing JR, Burnett A. Acute Myeloid Leukemia. [J]. N Engl J Med. 1999; 341 (14): 1051-62. |
| [25] | Austin R, Smyth MJ, Lane SW. Harnessing the immune system in acute myeloid leukaemia [J]. Crit Rev Oncol Hematol. 2016; 103: 62-77. |
| [26] | Davidson-Moncada J, Viboch E, Church SE, et al. Dissecting the Immune Landscape of Acute Myeloid Leukemia [J]. Biomedicines. 2018; 6 (4). |
| [27] | Gasparini C, Celeghini C, Monasta L, et al. NF-κB pathways in hematological malignancies [J]. Cellular and Molecular Life Sciences. 2014; 71 (11): 2083-102. |
| [28] | Wang M, Zhang C, Tian T, et al. Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-alpha-TNF Receptor-2 Pathway [J]. Front Immunol. 2018; 9: 1274. |
| [29] | Scala S. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment [J]. Clin Cancer Res. 2015; 21 (19): 4278-85. |
| [30] | Baldari S, Ubertini V, Garufi A, et al. Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications [J]. Cell Death Dis. 2015; 6: e1621. |
| [31] | Gurtner A, Starace G, Norelli G, et al. Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function [J]. J Biol Chem. 2010; 285 (19): 14160-9. |
| [32] | Draber P, Stepanek O, Hrdinka M, et al. LST1/A is a myeloid leukocyte-specific transmembrane adaptor protein recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to the plasma membrane [J]. J Biol Chem. 2012; 287 (27): 22812-21. |
| [33] | Cui Y, Konig J, Nies AT, et al. Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma [J]. Lab Invest. 2003; 83 (4): 527-38. |
| [34] | Haupt KA, Enright AL, Ferdous AS, et al. The molecular basis of LST-1 self-renewal activity and its control of stem cell pool size [J]. Development. 2019; 146 (20). |
| [35] | Hsu HM, Chu CM, Chang YJ, et al. Six novel immunoglobulin genes as biomarkers for better prognosis in triple-negative breast cancer by gene co-expression network analysis [J]. Sci Rep. 2019; 9 (1): 4484. |
| [36] | D'Aloia A, Berruti G, Costa B, et al. RalGPS2 is involved in tunneling nanotubes formation in 5637 bladder cancer cells [J]. Exp Cell Res. 2018; 362 (2): 349-61. |
| [37] | Zhang Q, Wang Q, Wu S, et al. Clinical implication and immunological characterisation of the ARF-GEF family member CYTH4 in ovarian cancer [J]. Autoimmunity. 2020; 53 (8): 434-42. |
| [38] | Kennedy BM, Harris RE. Cyclooxygenase and lipoxygenase gene expression in the inflammogenesis of breast cancer [J]. Inflammopharmacology. 2018. |
APA Style
Fenling Zhou, Yuli Cao, Daxia Cai, Jiajian Liang, Cuilan Deng, et al. (2021). Identification of Three Candidate Genes and Their Correlation with Drug Sensitivity in Acute Myeloid Leukemia. Cancer Research Journal, 9(4), 176-190. https://doi.org/10.11648/j.crj.20210904.11
ACS Style
Fenling Zhou; Yuli Cao; Daxia Cai; Jiajian Liang; Cuilan Deng, et al. Identification of Three Candidate Genes and Their Correlation with Drug Sensitivity in Acute Myeloid Leukemia. Cancer Res. J. 2021, 9(4), 176-190. doi: 10.11648/j.crj.20210904.11
AMA Style
Fenling Zhou, Yuli Cao, Daxia Cai, Jiajian Liang, Cuilan Deng, et al. Identification of Three Candidate Genes and Their Correlation with Drug Sensitivity in Acute Myeloid Leukemia. Cancer Res J. 2021;9(4):176-190. doi: 10.11648/j.crj.20210904.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.crj.20210904.11,
author = {Fenling Zhou and Yuli Cao and Daxia Cai and Jiajian Liang and Cuilan Deng and Gexiu Liu and Dongmei He},
title = {Identification of Three Candidate Genes and Their Correlation with Drug Sensitivity in Acute Myeloid Leukemia},
journal = {Cancer Research Journal},
volume = {9},
number = {4},
pages = {176-190},
doi = {10.11648/j.crj.20210904.11},
url = {https://doi.org/10.11648/j.crj.20210904.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20210904.11},
abstract = {Background: Acute myeloid leukemia (AML) is a common hematopoietic tumor with extremely high morbidity and mortality. This study was designed to explore candidate genes that were related to the poor prognosis of AML patients and analyze their relationship with drug sensitivity. Methods: Microarray databases were performed to screen the differentially expressed genes (DEGs). DAVID 6.8 was used for further functional enrichment analysis. The protein-protein interaction (PPI) network was constructed through STRING website and Cytoscape tool. Then, we analyzed and explored the mRNA transcription level, prognosis correlation, and drug sensitivity of the candidate genes in AML via multiple acknowledged databases including the GEPIA, BloodSpot, EMBL-EBI, UALCAN, LinkedOmics, and GSCALite databases. Results: A total of 181 up-regulated DEGs were screened. Three candidate genes (MAP2K3, LST1, and CYTH4) related to poor outcomes of AML patients were identified. Meanwhile, the high expression levels of the three genes were verified in AML patients and AML cell lines, the expression differences of three genes at AML different subtypes were demonstrated. Drug sensitivity analysis displayed the expression levels of MAP2K3, LST1, and CYTH4 were negatively related to drug resistance, indicating that the three genes were sensitive to certain small-molecule drugs (including targeted drugs and non-targeted drugs). Conclusion: In summary, MAP2K3, LST1, and CYTH4 may be potential prognostic indicators for AML, and may be associated with the sensitivity of certain small molecule drugs.},
year = {2021}
}
TY - JOUR T1 - Identification of Three Candidate Genes and Their Correlation with Drug Sensitivity in Acute Myeloid Leukemia AU - Fenling Zhou AU - Yuli Cao AU - Daxia Cai AU - Jiajian Liang AU - Cuilan Deng AU - Gexiu Liu AU - Dongmei He Y1 - 2021/12/24 PY - 2021 N1 - https://doi.org/10.11648/j.crj.20210904.11 DO - 10.11648/j.crj.20210904.11 T2 - Cancer Research Journal JF - Cancer Research Journal JO - Cancer Research Journal SP - 176 EP - 190 PB - Science Publishing Group SN - 2330-8214 UR - https://doi.org/10.11648/j.crj.20210904.11 AB - Background: Acute myeloid leukemia (AML) is a common hematopoietic tumor with extremely high morbidity and mortality. This study was designed to explore candidate genes that were related to the poor prognosis of AML patients and analyze their relationship with drug sensitivity. Methods: Microarray databases were performed to screen the differentially expressed genes (DEGs). DAVID 6.8 was used for further functional enrichment analysis. The protein-protein interaction (PPI) network was constructed through STRING website and Cytoscape tool. Then, we analyzed and explored the mRNA transcription level, prognosis correlation, and drug sensitivity of the candidate genes in AML via multiple acknowledged databases including the GEPIA, BloodSpot, EMBL-EBI, UALCAN, LinkedOmics, and GSCALite databases. Results: A total of 181 up-regulated DEGs were screened. Three candidate genes (MAP2K3, LST1, and CYTH4) related to poor outcomes of AML patients were identified. Meanwhile, the high expression levels of the three genes were verified in AML patients and AML cell lines, the expression differences of three genes at AML different subtypes were demonstrated. Drug sensitivity analysis displayed the expression levels of MAP2K3, LST1, and CYTH4 were negatively related to drug resistance, indicating that the three genes were sensitive to certain small-molecule drugs (including targeted drugs and non-targeted drugs). Conclusion: In summary, MAP2K3, LST1, and CYTH4 may be potential prognostic indicators for AML, and may be associated with the sensitivity of certain small molecule drugs. VL - 9 IS - 4 ER -
Information
Email: